Viridian Therapeutics, Inc.\DE (VRDN) Operating Income (2016 - 2025)

Historic Operating Income for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Q3 2025 value amounting to -$40.0 million.

  • Viridian Therapeutics, Inc.\DE's Operating Income rose 5206.88% to -$40.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$328.1 million, marking a year-over-year decrease of 1592.56%. This contributed to the annual value of -$299.0 million for FY2024, which is 1752.21% down from last year.
  • Latest data reveals that Viridian Therapeutics, Inc.\DE reported Operating Income of -$40.0 million as of Q3 2025, which was up 5206.88% from -$106.8 million recorded in Q2 2025.
  • Viridian Therapeutics, Inc.\DE's 5-year Operating Income high stood at -$14.1 million for Q3 2021, and its period low was -$106.8 million during Q2 2025.
  • For the 5-year period, Viridian Therapeutics, Inc.\DE's Operating Income averaged around -$53.1 million, with its median value being -$51.2 million (2023).
  • Data for Viridian Therapeutics, Inc.\DE's Operating Income shows a peak YoY increase of 6790.11% (in 2021) and a maximum YoY decrease of 18236.59% (in 2021) over the last 5 years.
  • Quarter analysis of 5 years shows Viridian Therapeutics, Inc.\DE's Operating Income stood at -$29.1 million in 2021, then crashed by 68.72% to -$49.1 million in 2022, then plummeted by 45.68% to -$71.5 million in 2023, then decreased by 22.38% to -$87.5 million in 2024, then skyrocketed by 54.26% to -$40.0 million in 2025.
  • Its Operating Income was -$40.0 million in Q3 2025, compared to -$106.8 million in Q2 2025 and -$93.9 million in Q1 2025.